Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib

J Invest Dermatol. 2017 Apr;137(4):951-954. doi: 10.1016/j.jid.2016.10.044. Epub 2016 Nov 22.

Authors

Brett King¹, Alfred Ian Lee², Jaehyuk Choi³

Affiliations

¹ Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA. Electronic address: brett.king@yale.edu.
² Department of Medicine, Section of Hematology, Yale School of Medicine, New Haven, Connecticut, USA.
³ Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Female
Humans
Hypereosinophilic Syndrome / complications
Hypereosinophilic Syndrome / drug therapy*
Janus Kinase Inhibitors / therapeutic use*
Male
Middle Aged
Nitriles
Piperidines / adverse effects
Piperidines / therapeutic use*
Pyrazoles / adverse effects
Pyrazoles / therapeutic use*
Pyrimidines / adverse effects
Pyrimidines / therapeutic use*
Pyrroles / adverse effects
Pyrroles / therapeutic use*
Skin Diseases / drug therapy*

Substances

Janus Kinase Inhibitors
Nitriles
Piperidines
Pyrazoles
Pyrimidines
Pyrroles
ruxolitinib
tofacitinib

Grants and funding